Erectile Dysfunction

Premature Ejaculation

Male Hair Loss

Obesity

Latest News & Info

Jan
19
2016
Hypoactive Sexual Desire Disorder (HSDD) and Addyi (Flibanserin)
 

      
   
   

Hypoactive [low] Sexual Desire Disorder (HSDD) is a condition where a woman has an ongoing lack of interest in sex, which can cause problems in relationships and personal distress.

HSDD is the most common female sexual dysfunction and approximately 1 in 10 women suffer from the condition.

On 18th August 2015 the U.S. FDA (Food and Drug Administration) approved the drug Flibanserin, to be sold in the USA as the brand name Addyi.
 
Addyi is the first and only treatment for acquired, generalized HSDD (a low sex drive) in women who have not gone through the menopause.

HSDD is acquired when symptoms occur (i.e. – a prolonged period of a relatively low level of interest in sex) after a period of “healthy” sexual interest (i.e. – a prolonged period of a relatively higher level of interest in sex, or whatever level of interest is “normal” or “average” for a given individual – this can vary widely from person to person, and can change in an individual for a wide variety of reasons).
 
Hypoactive Sexual Desire Disorder is a generalized diagnosis when it occurs, regardless of the type of sexual activity, the situation, or the sexual partner.

Just like every medicine, Addyi(Flibanserin) can cause side effects, such as severely low blood pressure (hypotension) and loss of consciousness (syncope).

It is important that patients must NOT drink alcohol while taking Addyi (Flibanserin), as the risks are increased and more severe. Health care professionals must assess the likelihood that patients will follow this instruction before prescribing Addyi (Flibanserin).   

“Because of a potentially serious interaction with alcohol, treatment with Addyi will only be available through certified health care professionals and certified pharmacies. Patients and prescribers should fully understand the risks associated with the use of Addyi before considering treatment.” Said Dr Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER)

Addyi (Flibanserin) is being approved with a Boxed Warning to emphasize the risks of severe low blood pressure and loss of consciousness in patients who drink alcohol during treatment wih Addyi (Flibanserin).

Addyi (Flibanserin) has been referred to as the “female Viagra”, but this is an inaccurate description, as Flibanserin targets the brain rather than the genitals.

Addyi (Flibanserin) is currently only legally available in the U.S. and there are currently no indications as to when (or if) it will be approved for use in the EU or UK.
 
For more info, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm
                                  https://www.addyi.com/